Docket #: S12-133
Novel Protocol For Generation of Cardiac Progenitor Cells and Cardiomyocytes from iPSCs
For the application of human pluripotent stem cell-derived cardiomyocytes in drug discovery, cardiotoxicity testing, disease modeling, and regenerative medicine large numbers of cells need to be derived from a variety of cell lines in a defined, reproducible and cost-efficient manner.
Researchers at Stanford's School of Medicine have developed a technique that enables the differentiation of human pluripotent stem cells to cardiomyocytes with high purity (>85% TNNT2+), efficiency and reproducibility. This technique has been demonstrated to function in a wide variety of hiPSC lines.
Applications
- Cardiotoxicity Testing
- Drug testing
- Disease Modeling
- Regenerative Medicine
Advantages
- High Yield
- Low Cost
- Reproducibility
Publications
- Published International Patent Application WO 2014078414 A1
Patents
- Published Application: 20140134733
- Published Application: WO2014078414
- Issued: 9,234,176 (USA)
Similar Technologies
-
LSRE-1 Hybridoma - MEL-14 - ATCC# HB-132 S83-075LSRE-1 Hybridoma - MEL-14 - ATCC# HB-132
-
Alpha 2b Adrenergic Receptor Gene Disruption Mouse (A2bARGDM) - Jackson Labs: Adra2b/tm1Gsb, Stock #002511 S97-237Alpha 2b Adrenergic Receptor Gene Disruption Mouse (A2bARGDM) - Jackson Labs: Adra2b/tm1Gsb, Stock #002511
-
MRI - Rapid Measurement of Blood Flow S02-048MRI - Rapid Measurement of Blood Flow